All In Biotech

Drug Trial Radar · NCT01091428

Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer

Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, Plus Weekly Paclitaxel or Weekly Paclitaxel Alone in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Preceded by a Phase 1 Portion in Patients With Ovarian or Breast Cancer

Last checked: Nov 19, 2026Latest source record: Jun 4, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 191 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

191

Actual

Start

Apr 16, 2010

Primary completion

Aug 12, 2014

Study completion Jul 19, 2017

Sponsor

Lead sponsor
Millennium Pharmaceuticals, Inc.Takeda (TAK)
Sponsor type
Industry
First posted
Mar 24, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multicenter study with a nonrandomized Phase 1 portion and an open-label, randomized, Phase 2 portion evaluating MLN8237 in combination with weekly paclitaxel in adult female participants with advanced breast cancer (Phase 1 portion only) and recurrent ovarian cancer (both Phase 1 and Phase 2 portions).

Conditions

  • Ovarian Carcinoma
  • Fallopian Tube Cancer
  • Peritoneal Cancer
  • Breast Carcinoma

Interventions

  • AlisertibDrug

    Alisertib tablets

  • PaclitaxelDrug

    Paclitaxel intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) for Alisertib in Combination With PaclitaxelTime frame: Cycle 1 (Up to 28 days)
  2. Phase 1: MTD and RP2D for Paclitaxel in Combination With AlisertibTime frame: Cycle 1 (Up to 28 days)
  3. Phase 1: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: First dose to 30 days past last dose (Up to 36 Months)
  4. Phase 1: Number of Participants With Clinically Significant Laboratory ValuesTime frame: First dose to 30 days past last dose (Up to 36 Months)
  5. Phase 1: Number of Participants With Clinically Significant Vital Sign FindingsTime frame: First dose to 30 days past last dose (Up to 36 Months)
  6. Phase 1: Number of Participants With Hypersensitivity and NeurotoxicityTime frame: Baseline up to Month 36
  7. Phase 2: Progression-Free Survival (PFS)Time frame: At the end of Cycle 2 and at the completion of every 2 cycles until PD was documented or up to data cut-off: 12 August 2014 (approximately 24 months)

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    The Bronx, New York

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Houston, Texas

  • Site not named

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.